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Summary
The ERG gene is fused to TMPRSS2 in approximately 50% of prostate cancers (PrCa) resulting in 
its overexpression. However, whether this is the sole mechanism underlying ERG elevation in 
PrCa is currently unclear. Here we report that ERG ubiquitination and degradation is governed by 
the Cullin 3-based ubiquitin ligase SPOP and that deficiency in this pathway leads to aberrant 
elevation of the ERG oncoprotein. Specifically, we find that truncated ERG (ΔERG), encoded by 
the ERG fusion gene, is stabilized by evading SPOP-mediated destruction, while prostate cancer-
associated SPOP mutants are also deficient in promoting ERG ubiquitination. Furthermore, we 
show that SPOP/ERG interaction is modulated by CKI-mediated phosphorylation. Importantly, we 
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demonstrate that DNA damage drug, topoisomerase inhibitors, can trigger CKI activation to 
restore the SPOP/ΔERG interaction and its consequent degradation. Thus SPOP functions as a 
tumor suppressor to negatively regulate the stability of the ERG oncoprotein in prostate cancer.
Introduction
Prostate cancer (PrCa) is the second leading cause of cancer death for men in western 
countries (Siegel et al., 2013). Extensive genomic studies revealed that PrCa is driven by 
accumulation of genetic alterations including PTEN loss (Li et al., 1997) and gene fusions 
(Tomlins et al., 2007). Gene fusion products, by juxtaposing two separate genes, may result 
in a chimeric protein with different functions, such as the BCR–ABL1 gene fusion in chronic 
myeloid leukemia (CML) (Ren, 2005). Alternatively, a proto-oncogene fusing to a strong 
promoter/enhancer can result in up-regulation of mRNA levels. For example, the IgH-Myc 
fusion in lymphoma (Adams et al., 1985) and the E26 transformation-specific (ETS) family 
of transcription factor fusions in prostate cancer (Kumar-Sinha et al., 2008).
The most common ETS gene fusion is TMPRSS2-ERG, which occurs in approximately 50% 
of prostate cancers (Kumar-Sinha et al., 2008; Tomlins et al., 2005). On the other hand, 
overexpression of other ETS genes such as ETV1, ETV4 and ETV5 due to gene fusion, have 
been reported in only 5–10% of prostate cancers (Rubin et al., 2011). Fusion of ERG to 
TMPRSS2 results in increased mRNA levels of ERG and expression of N-terminally 
truncated ERG protein under the control of androgen-regulated TMPRSS2 promoter 
(Tomlins et al., 2005). Recent studies have demonstrated that overexpression of ERG fusion 
proteins facilitate prostate cancer development largely by promoting cell migration and 
invasion (Carver et al., 2009b; Tomlins et al., 2008), thereby functioning as an oncogene. 
Moreover, the TMPRSS2-ERG fusion has been found in the prostate cancer precursor high-
grade prostatic intraepithelial neoplasia (HGPIN), indicating that it is an early molecular 
event associated with invasion in prostate cancer (Perner et al., 2007). Furthermore, the 
deubiquitinase USP9X interacts with and stabilizes ERG to promote prostate cancer (Wang 
et al., 2014). However, little is known about how ERG protein stability is physiologically 
governed by E3 ligase(s) in vivo and aberrantly regulated in prostate cancer.
Recently, systematic sequencing studies further revealed that recurrent somatic mutation is 
another key feature of prostate cancer (Barbieri et al., 2012; Berger et al., 2011). Notably, 
the most frequently mutated gene is SPOP (speckle-type POZ protein), which encodes a 
Cullin 3-based E3 ubiquitin ligase, with recurrent mutation in 6–15% of primary human 
prostate cancers (Barbieri et al., 2012; Lindberg et al., 2013). Structurally, SPOP contains 
two conserved domains: an N-terminal MATH domain that recruits substrates, and a C-
terminal BTB domain that binds Cullin 3 (Zhuang et al., 2009). Several SPOP substrates 
have been identified in the context of prostate, including the androgen receptor (AR) (An et 
al., 2014; Geng et al., 2014), steroid receptor coactivator 3 (SRC-3) (Li et al., 2011), DEK 
and TRIM24 (Theurillat et al., 2014). Furthermore, prostate cancer-associated SPOP 
mutants are deficient in binding with and promoting the degradation of substrates leading to 
increased prostate cancer cell proliferation and invasion (An et al., 2014; Barbieri et al., 
2012), indicating the loss-of-function of SPOP mutations and the tumor suppressive role of 
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SPOP in prostate cancer. Therefore, identification of additional SPOP substrates would 
benefit prostate cancer clinical diagnosis and therapy.
Interestingly, these two common genetic alterations (SPOP somatic mutations and ERG 
fusions) appear to be mutually exclusive in prostate cancer (Barbieri et al., 2012), but the 
reason for the segregation of these two genetic events remains largely unknown. Since both 
SPOP mutations and ERG fusion are tightly associated with prostate cancer development, 
they might affect similar downstream pathways or targets to facilitate prostate cancer 
progression.
Results
SPOP specifically interacts with and promotes ubiquitination and degradation of ERG
Given the prevalence and the critical role of ERG in prostate cancer progression (Carver et 
al., 2009a; Tomlins et al., 2008), it is important to understand how ERG protein stability is 
governed in vivo and whether it is aberrantly regulated in prostate cancer. To this end, we 
observed that the abundance of endogenous ERG protein levels were significantly increased 
upon treating PC3 and DU145 prostate cancer cells, which express very low protein levels 
of wild-type ERG, with the proteasome inhibitor MG132 (Figure 1A). Importantly, ERG 
protein abundance detected by western blot analysis was markedly reduced by multiple 
shERG vectors in PC3 cells, confirming that the ERG antibody specifically recognizes 
endogenous ERG in prostate cancer cells (Figure S1A). As the multi-subunit Cullin-Ring 
complexes are the largest known class of E3 ubiquitin ligases (Petroski and Deshaies, 2005), 
we next examined whether a specific Cullin-Ring complex contributes to ERG destruction. 
We found that ERG specifically interacted with Cullin 3, but not other members of the 
Cullin family (Figure 1B). Consistent with this finding, depletion of endogenous Cullin 3 led 
to an increase in ERG abundance (Figure 1C), indicating that the Cullin 3 pathway is 
involved in controlling ERG stability. Previous studies have established that Cullin 3 exerts 
its E3 ubiquitin ligase activity by recruiting various BTB/POZ domain-containing proteins 
as substrate-specific adaptors, including Keap1 and SPOP (Genschik et al., 2013). Notably, 
we observed that both ERG and ERF specifically interacted with SPOP, but not Keap1 or 
COP1, a Cullin 4-based E3 ligase substrate adaptor protein with a tumor suppressive role in 
prostate cancer (Vitari et al., 2011), in vivo and in vitro (Figures 1D and S1B–D). Consistent 
with this finding, we demonstrated that ectopic expression of SPOP, but not Keap1, 
decreased expression of ERG in a dose-dependent manner (Figures 1E, 1F and S1E). More 
importantly, SPOP-mediated destruction of ERG could be blocked by MG132 (Figure 1G).
Next, in keeping with a previous study (Vitari et al., 2011), we found that Cullin 4A/COP1 
promoted the destruction of ETV1, but not ERG or ERF (Figure 1H). On the other hand, 
SPOP specifically promoted ERG and ERF, but not ETV1, turnover (Figure 1I). We further 
confirmed that SPOP-WT, but not Keap1, COP1 or the E3 ligase activity-deficient mutant 
form of SPOP (SPOP-ΔBTB), could promote ERG ubiquitination in vivo (Figures 1J and 
S1F). These data together support the notion that the Cullin 3/SPOP E3 ligase complex 
specifically regulates ERG protein stability.
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SPOP negatively regulates ERG-mediated cell migration and invasion
Consistent with a critical role for SPOP in regulating ERG stability, depletion of 
endogenous SPOP by multiple shRNA vectors led to a noticeable accumulation in protein 
abundance of ERG, but not ETV1 or ERF, with minimal changes in ERG mRNA levels in 
prostate cancer cells (Figures 2A, 2B, S2A–C and Table S1). Hence, in the remainder of the 
study, we primarily focus on elucidating how SPOP controls the stability of the ERG 
protein. Importantly, the half-life of endogenous ERG protein was extended after depleting 
SPOP (Figures 2C and 2D), suggesting that SPOP controls ERG expression largely through 
a post-translational mechanism.
To explore the critical biological function of SPOP targeting ERG for degradation, we next 
examined the effects of SPOP depletion on cell proliferation, migration and invasion. In 
agreement with previous studies (Carver et al., 2009b; Tomlins et al., 2007; Tomlins et al., 
2008), we observed that depletion of SPOP or ERG has minor effects on cell growth and 
apoptosis in PC3 cells (Figures S2D–F). However, we found that depletion of ERG 
decreased cell migration (Figures 2E–G) and invasion (Figures S2G and S2H). In contrast, 
depletion of SPOP enhanced the invasive ability of the cells. More importantly, 
simultaneous depletion of SPOP and ERG reduced cell migration and invasion compared 
with SPOP single knockdown, arguing that SPOP modulates cell migration and invasion 
largely through governing ERG protein abundance (Figures 2E-2G, S2G and S2H). 
Consistent with these results, ERG target genes including ADAMTS1, CXCR4, OPN and 
MMP9, all of which play important roles in promoting cell migration and invasion (Carver 
et al., 2009b; Egeblad and Werb, 2002; Thalmann et al., 1999), were found to be 
upregulated at both the mRNA and protein levels upon SPOP depletion (Figures S2I, S2J 
and Table S1). Therefore, SPOP functions as a tumor suppressor in prostate by targeting the 
major prostate cancer driver ERG for ubiquitination and degradation. Together, these results 
suggest that SPOP is the physiological E3 ligase that promotes ERG ubiquitination and 
destruction in prostate cancer (Figure S2K).
Prostate cancer-associated SPOP mutants fail to interact with ERG to promote ERG 
destruction
All SPOP somatic mutations identified in prostate cancers, such as Y87C, F102C, W131G 
and F133V, are clustered in the MATH domain (Figure 3A) and display impaired substrate 
binding (Geng et al., 2013; Zhuang et al., 2009). To examine whether these SPOP mutations 
affect ERG stability, we first determined that deletion of the MATH domain abrogated 
SPOP binding to ERG (Figure 3B), while loss of either the MATH domain or the BTB 
domain inhibited SPOP-mediated ERG degradation (Figure 3C). Next, we found that 
various prostate cancer-associated SPOP mutants failed to interact with ERG (Figures 3D 
and S3A) to promote ERG ubiquitination and destruction (Figures 3E and 3F). On the other 
hand, ectopic expression of SPOP-WT, but not SPOP-mutants, resulted in a marked 
reduction of the half-life of endogenous or ectopically expressed ERG (Figures 3G, 3H and 
S3B, S3C). In keeping with a possible loss-of-function phenotype associated with SPOP 
mutants in promoting ERG destruction, only cells expressing wild-type, but not mutated, 
SPOP reduced endogenous ERG protein levels that subsequently led to decreased cell 
migration (Figures 3I, 3J and S3D–G).
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It has been previously reported that in prostate cancer cells, SPOP mutants are also deficient 
in promoting ubiquitination and subsequent degradation of NCOA3 (Geng et al., 2013), 
DEK and TRIM24 (Theurillat et al., 2014). To further examine the contribution of ERG or 
these above-mentioned SPOP substrates in mediating the tumorigenesis phenotypes in cells 
harboring SPOP mutations, we depleted each of these genes or ERG in DU145 cells stably 
expressing the well-characterized SPOP-F102C mutant (Zhuang et al., 2009). Notably, we 
found that depletion of each of these proteins leads to decreased cell migration, with 
depletion of ERG exhibiting the most significantly suppressive effects (Figures S3H–J). 
Furthermore, prostate cancer data sets from the cBio database (http://www.cbioportal.org/
public-portal) (Cerami et al., 2012) showed that ERG fusion occurs in approximately 50% of 
prostate cancers, whereas the frequency of aberrant NCOA3, DEK or TRIM24 expression is 
only 2–3% in the prostate cancer setting (Figure S3K). Hence, these results together indicate 
that ERG may be the major disease-relevant driver of prostate cancer. As such, SPOP 
mutations disrupt its ability to target ERG for ubiquitination, which may lead to aberrant 
elevation of ERG oncoprotein abundance to facilitate prostate cancer progression.
SPOP mutations contribute to elevated ERG protein levels and share common gene 
signatures with ERG fusion in clinical specimens
Having demonstrated SPOP as a physiological upstream E3 ligase for ERG, we next 
explored whether loss-of-function SPOP mutations correlated with elevated ERG protein 
levels in pathological conditions such as human prostate cancer. It is noteworthy that SPOP 
mutations are mutually exclusive with TMPRSS2-ERG fusion that leads to increased ERG 
expression at both the mRNA and protein levels (Barbieri et al., 2012; Clark and Cooper, 
2009). In keeping with this notion, we analyzed all of TCGA prostate cancer samples (236 
patients) and found that SPOP mutation and ERG fusion are mutually exclusive (Figures 
S3L and S3M).
However, some PrCa cases with moderate ERG protein levels did not harbor any ERG 
fusion (Park et al., 2010). We thus hypothesized that in ERG expression-positive but ERG 
fusion-negative cases, SPOP mutations may contribute to increased ERG protein levels. To 
test this notion, we generated a tissue microarray from 239 PrCa cases and identified 79 
ERG positive cases by IHC (Figure 3K). Using fluorescence in situ hybridization (FISH) 
analysis, we identified 14 of the 79 ERG IHC positive samples to be negative for 
TMPRSS2-ERG fusion (Figure 3L). Sanger sequencing analysis demonstrated that 5 of the 
14 cases harbored SPOP mutations (Figure S3N). Interestingly, besides the well-
characterized F133V mutation (Barbieri et al., 2012), we identified a novel SPOP mutation 
(R139K) located in the MATH domain and further validated that the R139K mutation was 
also deficient in promoting ERG degradation (Figure S3O). These results indicate that SPOP 
mutations likely contribute to the moderate ERG elevation in those prostate cancer cases 
without known ERG fusions, largely through stabilization of the ERG protein (Figure S3P).
To further understand the correlation between SPOP mutation and aberrant ERG expression 
in PrCa pathophysiology, we analyzed the gene signature of ERG fusion versus SPOP 
mutation in clinical specimens. By using two-class paired significance analysis of 
microarray data in tumor and normal samples within SPOP mutation cases and the 
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TMPRSS2-ERG fusion cases in TCGA, we found a significant correlation between the 
expression changes observed in tumors with SPOP mutations and in tumors with ERG 
fusion (Rho=0.64, P<2.2e-16) (Figure 3M). Compared with normal samples, 1100 and 9596 
genes showed significant differential expression in SPOP mutation and ERG fusion prostate 
tumor samples, respectively (Figure 3N). More importantly, there are 814 genes that are 
seemingly co-regulated by SPOP mutation and ERG fusion events with 574 up-regulated 
genes and 240 down-regulated genes (Figures 3N and 3O). These results support the notion 
that SPOP mutation and ERG fusion share common gene signatures. Therefore, SPOP 
mutation leads to increased expression of ERG protein and its targets to favor PrCa 
progression, which is similar to how the ERG fusion protein functions in PrCa.
SPOP-mediated ubiquitination and destruction of ERG depends on the SPOP binding motif
Consistent with previous reports that known SPOP substrates share a SPOP-binding 
consensus motif Φ-Π-S-S/T-S/T (Φ-nonpolar; Π-polar) (Zhuang et al., 2009), we found that 
ERG contains two putative SPOP binding motifs or “degrons” located in exon 4 and exon 11 
(Figures 4A and 6A). Notably, deletion of degron 1 (ΔDeg1) but not degron 2 (ΔDeg2) 
largely blocked SPOP-mediated ERG degradation, while ERG was no longer subjected to 
degradation by SPOP when both degrons 1 and 2 were deleted (ΔDeg1+2) (Figures 4B and 
S4A). These data suggest that degron 1 is the major SPOP binding site, while degron 2 plays 
a dispensable role in SPOP-mediated ERG destruction. Consistently, compared with wild-
type, deletion of degron 2 only moderately reduced, while deletion of degron 1 or both 
degrons dramatically decreased ERG interaction with SPOP in vivo and in vitro (Figures 4C 
and S4B). These results confirm degron 1 as the major functional degron in conferring 
SPOP-mediated destruction of ERG, thus ΔDeg1+2 and ΔDeg1 mutants behaved similarly 
in most assays we examined (Figures 4B, 4C, 4G and S4A, S4B). However, to be on the 
conservative side eliminating any possible contribution of degron 2 to ERG stability, 
ΔDeg1+2 mutant was used as the non-degradable version of ERG for biochemical and 
cellular assays hereafter. Moreover, in support of the critical role of identified degrons in 
mediating SPOP-dependent degradation of ERG, the half-life of ΔDeg1+2 was significantly 
extended compared with wild-type (Figures 4D and 4E), and the ubiquitination of degron-
deleted ERG was reduced in vitro and in vivo (Figures 4F and 4G). Next, we examined 
whether SPOP-mediated ERG degradation plays any physiological role in prostate cancer. 
Notably, ectopic expression of either ERG-WT or ΔDeg1+2 led to elevated mRNA levels of 
ERG targets (Figure S4C and Table S1) and as a result, significantly increased cell 
migration (Figures 4I and 4J). More importantly, co-expression with SPOP could suppress 
ERG-WT, but not ΔDeg1+2-mediated enhancement of cell migration (Figures 4I and 4J), 
which may be explained by the observation that ectopic expression of SPOP led to a 
significant reduction in the expression levels of ERG-WT, but not ΔDeg1+2 in vivo (Figure 
4H).
Casein kinase I phosphorylates ERG in the degron 1 to trigger SPOP/ERG interaction and 
promote degradation of ERG
Although proper substrate phosphorylation is required for recognition by many well-studied 
SCF type of E3 ubiquitin ligases, such as β-TRCP (Cardozo and Pagano, 2004) and FBW7 
(Welcker and Clurman, 2008), it is unclear whether similar modifications are needed for 
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Cullin 3-based SPOP E3 ligase recognition of its substrates. In support of this notion, a 
recent study identified that SPOP promoted SRC-3 degradation in a CKIe-dependent manner 
(Li et al., 2011). In keeping with the fact that ERG and SRC-3 share a similar degron 
sequence with a stretch of Ser/Thr residues (Figure 5A), we found that the interaction of 
ERG with SPOP was significantly reduced upon lambda protein phosphatase (λ-PPase) 
treatment (Figure 5B), indicating that phosphorylation of ERG may facilitate ERG and 
SPOP interaction. Next, we attempted to identify the kinase(s) responsible for ERG 
phosphorylation. The Scansite program (http://scansite.mit.edu) predicted that the Ser/Thr 
residues in the ERG degrons are likely CKI or CKII sites. Interestingly, only CKId, but not 
other CKI isoforms or CKII could promote ERG degradation under ectopic expression 
conditions (Figure 5C). In contrast, we found that the CKI inhibitor IC261 or D4476 
treatment resulted in accumulation of ERG (Figure S5A). Importantly, using in vitro kinase 
assays, we further demonstrated that deletion of degron 1 largely abolished CKI-mediated 
phosphorylation of ERG (Figure S5B), indicating that serine residues within degron 1 are 
the major CKI phosphorylation sites.
Consistent with these results, CKI inhibitor treatment significantly decreased SPOP and 
ERG interaction (Figures S5C and S5D), whereas phosphorylation of ERG within degron 1 
by CKI in vitro or co-overexpression of CKIδ in cells enhanced the association of ERG with 
SPOP to promote ERG ubiquitination (Figures 5D-5F). Importantly, ΔDeg1+2 exhibited 
significant resistance to CKIδ-mediated ERG degradation (Figure 5G). These results 
indicate that phosphorylation of ERG by CKIδ within the SPOP-recognition degron triggers 
its interaction with SPOP to promote ERG destruction (Figure S5M). More importantly, 
when expressed at comparable levels, CKIδ could suppress ERG-WT, but not ΔDeg1+2-
mediated enhancement of cell migration (Figures 5G-5I). Moreover, cell migration was 
significantly enhanced by inactivating CKIδ via either depleting endogenous CKIδ (Figures 
S5E–G) or the use of CKI inhibitors (Figures S5H and S5I). On the other hand, 
overexpression of CKIδ could conversely, inhibit cell migration in a dose-dependent manner 
(Figures S5J–L).
In support of serine residues in degron 1 being major CKI-mediated phosphorylation sites, 
in vivo Ser46 phosphorylation is detected by high-resolution tandem mass spectrometry 
(LC-MS/MS) analysis (Figure S5N). However, mutating S46 to an alanine alone could not 
diminish CKI-mediated ERG phosphorylation in vitro (Figure 5J), indicating that other 
serine residues within degron 1 may be CKI phosphorylation sites. In support of this notion, 
mutating S44, S45 and S46 to alanines (ERG-3A) largely abolished CKI-mediated 
phosphorylation of ERG in vitro (Figure 5J). Consistently, the ERG-3A mutant displayed a 
marked elevation of resistance to CKIδ-mediated ERG degradation (Figure 5K) and 
deficiency in SPOP/CKI-mediated ubiquitination in cells (Figure 5L). As a result, ERG-3A 
displayed significantly reduced interaction, whereas the phospho-mimetic mutant, ERG-3D, 
exhibited relatively enhanced interaction, with SPOP in cells (Figure 5M). As a 
consequence, SPOP could efficiently suppress cell migration induced by ERG-WT, but not 
ERG-3A (Figures 5N–P). These results coherently suggest that CKI functions as the 
upstream modifying kinase that phosphorylates multiple serine residues within degron 1 and 
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subsequently enhances SPOP-mediated degradation of ERG to govern its biological 
functions.
Impaired association between SPOP and TMPRSS2-ERG fusion proteins can be restored 
by CKI-mediated phosphorylation
The most frequently detected ERG fusion transcripts are the TMPRSS2 exon 1 fused to 
ERG exon 4 or exon 5, with exon 4 fusion being the predominant form (Clark et al., 2007). 
Both fusions encode N-terminally truncated ERG proteins, which lack the first 39 or 99 
amino acids (designated ERG-Δ39 and ERG- Δ99, respectively) (Figure 6A). As a result, the 
TMPRSS2-ERG fusion results in androgen-induced overexpression of ERG at both mRNA 
and protein levels, which facilitates prostate cancer progression largely by promoting cell 
migration and invasion (Carver et al., 2009b; Tomlins et al., 2008).
Given that the ETV1 fusion protein is insensitive to COP1-mediated degradation (Vitari et 
al., 2011), we next examined whether these ERG fusion proteins are resistant to SPOP-
mediated degradation. Notably, in keeping with our observation that degron 1 is the major 
degron while degron 2 is largely nonfunctional in mediating SPOP-dependent ERG 
degradation (Figures 4A-4C), ERG- Δ99 that lacks degron 1 could not be degraded by SPOP 
(Figure 6B). However, although ERG- Δ39 contains both degrons, it displayed significant 
resistance to SPOP-mediated degradation (Figure 6B). Mechanistically, ERG-D39 displayed 
significantly reduced capability, while ERG- Δ99 completely failed, to interact with SPOP 
both in vivo and in vitro (Figures 6C and S6A). As the identified degron 1 (aa 42–46) is in 
close proximity to the fusion break point, it is possible that deletion of the first 39 amino 
acids may cause a conformational change, leading to the masking of the otherwise 
recognizable degron 1. This led us to hypothesize that unlike ERG-Δ99 that lacks degron 1, 
the interaction of ERG-Δ39 with SPOP might be restored upon the re-exposure of degron 1. 
In keeping with this notion, we found that CKI-dependent phosphorylation of degron 1, 
which could enhance SPOP interaction with WT-ERG (Figures 5D and 5E), could also 
facilitate the interaction between SPOP and ERG-Δ39 (Figure 6D). Furthermore, ectopic 
expression of CKIδ could trigger SPOP-dependent degradation (Figure 6E) and 
ubiquitination of ERG-Δ39, but not ERG-Δ99 (Figure 6H). Consistent with these results, the 
half-life of ERG-Δ39 and ERG-Δ99 was significantly extended (Figures 6F and 6G). 
Clinically, this is of significant importance, as fusion between TMPRSS2 and ERG exon 4 
comprises the largest population of fusion-positive prostate cancer cases and restoration of 
SPOP-mediated degradation of this ERG fusion protein could therefore inhibit 
tumorigenesis promoted by such a gene fusion in a large patient population.
Etoposide promotes the degradation of ERG fusion proteins in a SPOP and CKIδ 
dependent manner
However, due to the current lack of CKI agonists, we went on to explore whether DNA 
damaging agents, which have been reported to activate CKIδ in part by triggering its nuclear 
localization (Alsheich-Bartok et al., 2008; Wang et al., 2012), could also promote SPOP-
mediated destruction of TMPRSS2-ERG protein. Indeed, we found that DNA damaging 
drugs, mainly topoisomerase inhibitors including etoposide and doxorubicin, could trigger 
CKIδ nuclear translocation (Figure S6B) and significantly reduced the protein levels of 
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TMPRSS2-ERG fusion in VCaP cells (Figure 6I), in part by restoring the interaction 
between SPOP and TMPRSS2-ERG (Figure 6J). On the other hand, docetaxel, a clinically 
well-established anti-mitotic chemotherapy drug for prostate cancer (Tannock et al., 2004), 
had no significant effect on the abundance of TMPRSS2-ERG fusion protein (Figure 6I). 
Since androgen receptor protein levels were also moderately changed upon doxorubicin, but 
not etoposide treatment (Figure 6I), which might affect ERG mRNA levels, we chose to 
focus on etoposide to further study how DNA damage might govern ERG stability in the 
reminder of the study. Notably, we found that etoposide down-regulated TMPRSS2-ERG 
protein levels in VCaP cells in both a time and dose-dependent manner (Figures 6K and 6L) 
largely through shortening its protein half-life (Figures 6M and S6C). More importantly, 
etoposide-induced ERG reduction could be blocked by MG132 (Figure 6N), indicating that 
etoposide regulates ERG expression largely in an ubiquitination-dependent post-
translational manner. Consistently, we found that etoposide treatment led to an enhanced 
association of TMPRSS2-ERG with endogenous SPOP (Figure 6O), which subsequently 
resulted in an elevated ubiquitination of TMPRSS2-ERG that could be reduced by treatment 
with the CKI inhibitor, IC261 (Figure 6P).
Consistent with our finding of SPOP as an E3 ubiquitin ligase in controlling ERG stability, 
we found that depletion of endogenous SPOP largely abolished etoposide-triggered 
degradation of both TMPRSS2-ERG (Figure 6Q) and WT-ERG (Figure S6D). Notably, 
although inhibiting CKI in prostate cancer cell lines with WT-ERG background resulted in 
accumulation of ERG-WT (Figure S5A) and enhancement of cell migration (Figures S5H 
and S5I), CKI inhibitors did not significantly affect TMPRSS2-ERG protein levels and cell 
migration in VCaP cells (Figures S6E–F). This is in keeping with the notion that TMPRSS2-
ERG fusion escapes the SPOP/CKI degradation unless cells are challenged with etoposide to 
restore SPOP/CKI-mediated ERG ubiquitination (Figure 6V). Consistently, inactivation of 
CKIδ by either depletion of CKIδ (Figure 6R) or the use of CKI inhibitors IC261 and D4476 
(Figure 6S) efficiently blocked etoposide-induced TMPRSS2-ERG degradation.
Moreover, consistent with the observation that CKI-dependent phosphorylation facilitates 
SPOP-mediated degradation of WT-ERG, we found that etoposide also triggered the 
degradation of endogenous WT-ERG in both PC3 and LNCaP cells (Figures S6G and S6H), 
a process that could be blocked by treatment with CKI inhibitor (Figures S6I and S6J). As a 
result, in VCaP cells harboring ERG fusion (Figures 6T and 6U), as well as in WT-ERG 
expressing PC3 (Figures S6K and S6L) and LNCaP cells (Figures S6M and S6N), cell 
migration ability was significantly decreased upon etoposide treatment, which could be 
further restored by CKI inhibitor. Moreover, depleting SPOP attenuated the effects of 
etoposide in suppressing prostate cancer cell migration (Figures S6O and S6P), illustrating a 
critical physiological role for SPOP in mediating etoposide-induced destruction of ERG. 
Altogether, these results suggest that etoposide could suppress prostate cancer cell migration 
by promoting the degradation of both ERG-WT and ERG fusion proteins in a SPOP and 
CKIδ dependent manner.
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Discussion
The recurrent ERG fusion with TMPRSS2 and other partners discovered by the Chinnaiyan 
group have been widely considered as one of the most important molecular findings in 
prostate cancer in the past several decades (Tomlins et al., 2005). Importantly, it is an early 
and frequent event (over 50% of prostate cancer). Thus, it is well accepted that ERG 
overexpression plays a pivotal role in promoting prostate cancer progression (Rubin et al., 
2011). Here we provide experimental evidence demonstrating that the E3 ubiquitin ligase 
SPOP plays a critical tumor suppressive role in prostate cancer by controlling ERG 
oncoprotein stability.
Although previous studies and our results (Figure S6Q) indicated that SPOP could indirectly 
regulate the expression of ERG by targeting AR ubiquitination and degradation (An et al., 
2014; Geng et al., 2014), our work provides evidence that SPOP could also directly control 
the protein levels of ERG in a post-translational manner. Consistently, mutations at the E3 
ubiquitin ligase (SPOP) level to disrupt SPOP/ERG interaction, or fusions at the substrate 
(ERG) level to impair the degron, can prevent SPOP-mediated destruction of the ERG 
oncoprotein, leading to stabilization of ERG (Figure S2K). Moreover, it is widely accepted 
that ERG fusion events are predominant in prostate cancer and most ERG fusions lost the 
first 3 or 4 exons (Clark and Cooper, 2009). Thus, our current study provides a possible 
mechanism to explain why ERG fusion proteins are more stable, in part by evading SPOP-
mediated degradation.
Furthermore, we found that SPOP mutations and ERG fusion share common gene signatures 
in clinical specimens (Figures 3M-3O). These results further support the notion that aberrant 
activation of ERG signaling, either by genetic fusion events to shed off the degron 
sequences in ERG, or by mutating the upstream SPOP E3 ubiquitin ligase, will lead to the 
activation of a cohort of common substrates to favor prostate cancer development (Figure 
S3P). Therefore, our study provides a possible molecular mechanism underlying the mutual 
exclusivity of SPOP mutation and ERG fusion.
However, as the TMPRSS2-ERG gene product alone is not sufficient to drive prostate 
tumorigenesis (Carver et al., 2009b; Tomlins et al., 2008), it is possible that SPOP mutation 
might affect ERG and other oncogenic pathways, or cooperates with other genetic 
alterations such as PTEN loss to facilitate prostate tumorigenesis (Carver et al., 2009b; King 
et al., 2009). Nonetheless, given the prevalence of TMPRSS2-ERG fusion in prostate cancer 
and its role in prostate cancer progression, it is of significance that DNA damaging drugs 
such as etoposide facilitates the degradation of ERG fusion proteins in part by promoting 
nuclear accumulation of CKIδ to trigger SPOP-mediated degradation of ERG fusion proteins 
(Figure 6V). Importantly, as ERG fusions have been reported to be mutually exclusive with 
SPOP mutations (Barbieri et al., 2012), the preferable presence of WT-SPOP in most ERG-
fusion prostate cancer cases makes it possible to restore SPOP-mediated ubiquitination and 
degradation of TMPRSS2-ERG as a prostate cancer treatment strategy. Moreover, we 
identified that cells stably expressing SPOP mutants or the non-degradable ERG-Δ99 fusion 
protein, but not ERG-WT or ERG-Δ39, displayed resistance to etoposide-induced 
suppression of cell migration (Figures S6R–V). These results indicate that in clinical 
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settings, deficiencies in SPOP-mediated ERG degradation in patients with either SPOP 
mutation or ERG-Δ99 fusion may prevent a desirable clinical outcome. To this end, optimal 
treatment strategy based on genetic status may provide better and personalized clinical 
treatments for individual prostate cancer patient.
Experimental Procedures
In vivo ubiquitination assay
PC3 cells were transfected with His-ub and the desired constructs. Thirty-six hours post-
transfection, cells were treated with 20 µM MG132 for 6 hr. Cells were lysed in buffer A (6 
M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 µM imidazole, pH 8.0) and sonicated. The 
lysates were incubated with Ni-NTA matrices (Qiagen) for 3 hr at room temperature. The 
His pull-down products were washed twice with buffer A, twice with buffer A/TI (1 volume 
buffer A and 3 volume buffer TI) and one time with buffer TI (25 mM Tris-HCl, 20 mM 
imidazole, pH 6.8). The pull-down proteins were resolved by SDS-PAGE for 
immunoblotting.
Migration and invasion assay
For cell migration, 2×104 to 2×105 cells were plated in an 8.0 µm 24-well plate chamber 
insert (Corning, 3422) with serum-free medium on the top of insert and 3T3 conditional 
medium containing 10% FBS at the bottom of the insert. Cells were incubated for 24 hr and 
fixed with 4% paraformaldehyde for 15 min. After washed with PBS, cells on the top of the 
insert were scraped with a cotton swab. Cells adherent to the bottom were stained with 0.5% 
crystal violet blue for 15 min and then washed with ddH2O. The positive staining cells were 
examined under microscope. For cell invasion assay, Corning BioCoat GFR Matrigel 
Invasion Chambers (354483) were used instead of chamber insert used in migration assay. 
The following steps were performed as migration assay described above.
In vitro kinase assay
In vitro kinase assays were adapted from described previously (Inuzuka et al., 2010). 
Briefly, about 2 µg of bacterially purified ERG was incubated with CKI kinase in the 
presence of 1 µM ATP and kinase reaction buffer (10 µM Tris-HCl, pH7.5, 10 mM MgCl2, 
0.1 mM EDTA and 2 mM DTT) at 30°C for 30 min.
Real-time RT-PCR analysis
In vitro kinase assays were performed according to the protocol as described (Inuzuka et al., 
2010) with minor modifications.
Tissue microarray (TMA), Immunohistochemistry (IHC) and FISH
The construction of tissue microarray (TMA) from cases of prostatectomy has been 
described previously (Huang et al., 2005). Briefly, cases of prostatectomy (n=239) were 
reviewed and the areas of PrCa and benign prostate tissue circled separately. Three cores of 
PrCa and benign prostate were taken from each case and transferred to two recipient blocks 
to construct the TMAs. A 5 µm section was cut from each of the TMA blocks and used for 
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immunohistochemical (IHC) study. Anti-ERG antibody was purchased from Epitomics 
(AC-0105, clone EP111), and the IHC was performed as described previously (Park et al., 
2010). Detection of TMPRSS2-ERG gene fusion by Fluorescence In-Situ Hybridization 
(FISH) has been described previously (Schelling et al., 2013).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• The E3 ubiquitin ligase SPOP promotes ERG degradation in a CKI-dependent 
manner
• Prostate cancer-associated SPOP mutants fail to promote ERG destruction
• ERG fusion proteins evade SPOP-mediated degradation and could be restored 
by CKI
• Etoposide-induced ERG fusion protein degradation depends on SPOP and CKI
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Figure 1. SPOP specifically interacts with the Cullin 3/SPOP E3 ubiquitin ligase
A. Immunoblot (IB) analysis of whole cell lysates (WCL) derived from PC3 and DU145 
cells. Where indicated, cells were treated with 10 µM MG132 for 10 hr before harvesting.
B. IB analysis of WCL and immunoprecipitates (IP) derived from 293T cells transfected 
with indicated constructs. Cells were treated with 10 µM MG132 for 10 hr before 
harvesting.
C. IB analysis of WCL derived from PC3 cells infected with the indicated lentiviral shRNA 
vectors.
D. IB analysis of LNCaP WCL and anti-ERG IP. Rabbit IgG was used as a negative control 
for the IP. Cells were treated with 10 µM MG132 for 10 hr before harvesting.
E-I. IB analysis of WCL derived from 293 cells (E, G-I) or PC3 cells (F) transfected with 
indicated plasmids. Where indicated, 10 µM MG132 was added for 10 hr before harvesting.
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J. IB analysis of WCL and His pull-down products derived from PC3 cells transfected with 
plasmids expressing the indicated proteins.
See also Figure S1
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Figure 2. Depletion of SPOP leads to increased ERG protein levels and cell migration and 
invasion
A. Immunoblot (IB) analysis of whole cell lysates (WCL) derived from PC3 cells infected 
with the indicated lentiviral shRNA vectors.
B. Real-time PCR analysis to examine the ERG and SPOP mRNA levels after depletion of 
SPOP. Data was shown as mean ± SD for three independent experiments.
C-E. IB analysis of PC3 cells infected with the indicated lentiviral shRNA constructs (C, E). 
Where indicated, 100 µg/ml cycloheximide (CHX) was added and cells were harvested at 
indicated time points. ERG protein abundance in (C) was quantified by ImageJ and plotted 
as indicated (D).
F-G. Representative images of migrated PC3 cells infected with indicated lentiviral shRNA 
constructs in migration assay (F) and quantification of migrated cells (G). Data was shown 
as mean + SD for three independent experiments. **p < 0.001, t-test.
See also Figure S2
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Figure 3. Prostate cancer-associated SPOP mutants fail to regulate ERG stability
A. Schematic of SPOP domains and prostate cancer-associated mutations.
B. Immunoblot (IB) analysis of whole cell lysates (WCL) and immunoprecipitates (IP) 
derived from 293T cells transfected with indicated constructs. Cells were treated with 10 µM 
MG132 for 10 hr before harvesting.
C. IB analysis of 293T cells transfected with the indicated plasmids.
D. IB analysis of WCL and IP derived from 293T cells transfected with indicated constructs. 
Cells were treated with 10 µM MG132 for 10 hr before harvesting.
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E. IB analysis of 293T cells transfected with the indicated plasmids.
F. IB analysis of WCL and His pull-down products derived from PC3 cells transfected with 
plasmids expressing the indicated proteins.
G. IB analysis of WCL derived from DU145 cells stably expressing SPOP-WT or mutants. 
Cells were treated with 100 µg/ml cycloheximide (CHX) for the indicated time period before 
harvesting.
H. ERG protein abundance in (G) was quantified by ImageJ and plotted as indicated.
I. Representative images of migrated DU145 cells infected with the indicated lentiviral 
shRNA constructs in migration assays.
J. Quantification of migrated cells in (I). Data was shown as mean ± SD for three 
independent experiments. *p < 0.05, t-test.
K. Protein levels of ERG were up-regulated in human prostate cancer samples but not in 
comparable benign prostate tissue. The tissue microarray slide was stained with anti-ERG 
antibody (left). High power views of negative and positive nuclear staining of ERG were 
shown (right).
L. Identification of TMPRSS2-ERG status by FISH in cases with positive staining in (K). 
The green signal (ERG) is separated or split from the red-aqua signal pair (TMPRSS2-ERG 
fusion) in ERG fusion (+) samples but not ERG fusion (−) samples.
M. Gene expression changes were positive correlation in SPOP mutation and ERG fusion 
clinical specimens. Please refer to supplemental information for details.
N. SPOP mutation and ERG fusion share common gene signature. Venn diagram showing 
the overlap of genes significantly differentially expressed in SPOP mutation and ERG fusion 
samples from TCGA.
O. Heatmap of the common genes associated with SPOP mutation and ERG fusion. N 
represents matched normal samples from ERG fusion or SPOP mutation patients; T 
represents matched tumor samples from ERG fusion or SPOP mutation patients; the number 
represents TCGA patient ID.
See also Figure S3
Gan et al. Page 20
Mol Cell. Author manuscript; available in PMC 2016 September 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. SPOP promotes ERG ubiquitination and destruction depending on the degron motif
A. Sequence alignment of ERG with the SPOP binding motif (degron) in known SPOP 
substrates.
B. Immunoblot (IB) analysis of whole cell lysates (WCL) derived from 293T cells 
transfected with indicated constructs.
C. IB analysis of WCL and GST pull down products derived from 293T cells transfected 
with indicated constructs. Cells were treated with 10 µM MG132 for 10 hr before 
harvesting.
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D. IB analysis of WCL derived from 293T cells transfected with indicated HA-ERG 
plasmids. Cells were treated with 100 µg/ml cycloheximide (CHX) for the indicated time 
period before harvesting.
E. ERG protein abundance in (D) was quantified by ImageJ and plotted as indicated.
F. The SPOP/Cullin 3 complex promotes ERG ubiquitination in vitro. Please refer to 
supplemental information for experimental details.
G. IB analysis of WCL and His tag pull-down products derived from PC3 cells transfected 
with plasmids expressing the indicated proteins.
H. IB analysis of PC3 cells transfected with the indicated constructs.
I-J. Representative images of migrated PC3 cells transfected with indicated constructs in 
migration assay (I) and quantification of migrated cells (J). Data was shown as mean ± SD 
for three independent experiments. **p < 0.001, t-test.
See also Figure S4
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Figure 5. CKI triggers the SPOP and ERG interaction to promote ERG degradation
A. Sequence alignment of ERG with the phospho-degron in SRC-3, a known SPOP 
substrate.
B. In vitro GST pull-down assay demonstrate that SPOP/ERG interaction is phosphorylation 
dependent.
C. Immunoblot (IB) analysis of 293T cells transfected with indicated constructs.
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D. GST-SPOP proteins purified from 293T cells were pulled-down with bacterially purified 
His-ERG-N200 prior treated with or without CKI kinase for 30 min. The samples were 
subjected to IB analysis.
E. IB analysis of WCL and IP derived from 293T cells transfected with indicated plasmids. 
Cells were treated with 10 µM MG132 for 10 hr before harvesting.
F. IB analysis of WCL and His tag pull-down products derived from PC3 cells transfected 
with the indicated plasmids.
G. IB analysis of 293T cells transfected with the indicated constructs.
H-I. Representative images of migrated PC3 cells transfected with indicated constructs in 
migration assay (H) and quantification of migrated cells (I). Data was shown as mean ± SD 
for three independent experiments. **p < 0.001, t-test.
J. In vitro kinase assays to demonstrate that ERG-3A mutant cannot be phosphorylated by 
CKI.
K. IB analysis of 293T cells transfected with the indicated constructs.
L. IB analysis of WCL and His tag pull-down products derived from PC3 cells transfected 
with the indicated plasmids.
M. In vitro GST-pull down assays to demonstrate a decreased interaction between GST-
SPOP and the ERG-3A mutant.
N. IB analysis of 293T cells transfected with the indicated constructs.
O-P. Representative images of migrated PC3 cells transfected with indicated constructs in 
migration assays (O) and quantification of migrated cells (P). Data was shown as mean + 
SD for three independent experiments. **p < 0.001, t-test.
See also Figure S5
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Figure 6. Etoposide-induced degradation of TMPRSS2-ERG fusion proteins is dependent on 
SPOP and CKIδ
A. Schematic of major putative TMPRSS2-ERG fusion protein products and the degrons.
B. Immunoblot (IB) analysis of whole cell lysates (WCL) derived from 293T cells 
transfected with the indicated constructs.
C-D. IB analysis of WCL and GST pull down products derived from 293T cells transfected 
with indicated constructs. Cells were treated with 10 µM MG132 for 10 hr before 
harvesting.
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E-G. IB analysis of WCL derived from 293T cells transfected with the indicated constructs 
demonstrate that CKIδ triggers SPOP-mediated degradation of the ERG-Δ39 fusion product 
(E) by shortening its half-life measured by CHX chase assay (F-G).
H. In vivo ubiquitination assay analysis of WCL and His tag pull-down products derived 
from PC3 cells transfected with the indicated plasmids.
I. IB analysis of VCaP cells treated with various DNA damage drugs for 12 hr.
J. In vivo GST-pull down analysis to demonstrate that etoposide treatment restore SPOP 
interaction with the ERG-Δ39 fusion product.
K-L. IB analysis of WCL derived from PC3 cells treated with 20 µM etoposide for indicated 
time (K) or treated with etoposide for 12 hr (L) before harvesting.
M. IB analysis of VCaP cells treated with etoposide for 12 hr before performing CHX chase 
analysis.
N. IB analysis of VCaP cells treated with etoposide or together with MG132 for 12 hr before 
harvesting.
O. IB analysis of WCL and anti-ERG IP derived from VCaP cells.
P. IB analysis of WCL and His tag pull-down products derived from PC3 cells transfected 
with the indicated plasmids.
Q-R. IB analysis of WCL derived from VCaP cells infected with the indicated lentiviral 
shRNA constructs. Cells were treated with 20 µM etoposide for 12 hr before harvesting.
S. IB analysis of VCaP cells treated with etoposide and CKI inhibitors IC261 (50 µM) and 
D4476 (20 µM) for 12 hr before harvesting.
T-U. Representative images of migrated VCaP cells treated with etoposide (Eto) or together 
with CKI inhibitor (IC261) in migration assay and quantification of migrated cells in (T). 
Data was shown as mean ± SD for three independent experiments. **p < 0.001, t-test.
V. A schematic illustration of the proposed model of mechanistically how DNA damaging 
agents including etoposide could promote nuclear translocation of CKIδ, thereby triggering 
CKI-dependent phosphorylation of the otherwise non-recognizable degron present in the 
ERG-Δ39 fusion product, restoring its interaction with SPOP and subsequent ubiquitination 
and degradation by the Cullin 3/SPOP E3 ligase.
See also Figure S6
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